Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody®

- Results of dose escalation portion from phase 1b/2 trials of ADG126 in combination with anti-PD-1 therapies, including confirmed clinical responses, pave...

Related Keywords

United States , Japan , Australia , Florida , Orlando , Singapore , China , Suzhou , Jiangsu , , Twitter , European Union , Linkedin , Adagene Inc , Dynamic Precision Library , Nasdaq , Safety Profile Reinforced , Clinical Responses , Tumor Shrinkage , Prolonged Stable Disease Supports , Dose Expansion Ongoing , Tumor Potential Shown , Nasdaq Adag , Dagene Inc ,